Pub Date : 2021-07-23DOI: 10.51626/ijor.2021.02.00005
Background and aims: Ionizing radiation (IR) are a well-known carcinogenic agent, acting through genotoxic mechanisms. In the last years, great attention has been paid to the effects of IR at low doses and to the non-monotonic dose-response curve for IR exposures. To improve the knowledge of IR-mediated effects and possibly identify biomarkers for IR effects, we combined the Cell Transformation Assay (CTA) with transcriptomics, to correlate cytotoxicity and transformation endpoints with the modulation of gene profiles after IR exposure. Methods: BALB/c3T3 cells were exposed to ionizing radiation ranging from 0.25Gy and 6Gy. Irradiated cells were seeded for the CTA 20h later. At the same time, RNA was extracted for microarray experiments. The cell clonal survival was significantly increased in 0.25Gy IR exposed cells, while the 3Gy dose strongly inhibited cellular growth. Cell transformation was observed only at the highest dose (3Gy). Results: Cell’s transformation was observed at 1.5, 2 and 3Gy doses. The 0.25Gy dose, which was able to induce an increment of clonal efficiency, did not induce cell transformation. The gene expression profile, which was obtained by comparing cells treated with the highest tested dose of 3Gy with the cells exposed to the lowest, not transforming, dose of 0.25Gy, identified several genes related to mitotic cell cycle and cholesterol biosynthesis. Conclusion: Our study showed that the up-regulation of genes belonging to the Spindle Assembly Checkpoint and mitosis progression could support the transforming ability of the 3Gy BALB/c3T3 exposed cells, probably through the involvement of genomic instability. Gene transcripts involved into cholesterol biosynthesis appear to be critical, as well. All these transcripts may be regarded as potential biomarkers of IR effects.
{"title":"Transcriptomics and Cell Transformation Assay: an Integrated Approach to Evaluate the Effects of Low Dose Ionizing Radiation","authors":"","doi":"10.51626/ijor.2021.02.00005","DOIUrl":"https://doi.org/10.51626/ijor.2021.02.00005","url":null,"abstract":"Background and aims: Ionizing radiation (IR) are a well-known carcinogenic agent, acting through genotoxic mechanisms. In the last years, great attention has been paid to the effects of IR at low doses and to the non-monotonic dose-response curve for IR exposures. To improve the knowledge of IR-mediated effects and possibly identify biomarkers for IR effects, we combined the Cell Transformation Assay (CTA) with transcriptomics, to correlate cytotoxicity and transformation endpoints with the modulation of gene profiles after IR exposure.\u0000Methods: BALB/c3T3 cells were exposed to ionizing radiation ranging from 0.25Gy and 6Gy. Irradiated cells were seeded for the CTA 20h later. At the same time, RNA was extracted for microarray experiments. The cell clonal survival was significantly increased in 0.25Gy IR exposed cells, while the 3Gy dose strongly inhibited cellular growth. Cell transformation was observed only at the highest dose (3Gy).\u0000Results: Cell’s transformation was observed at 1.5, 2 and 3Gy doses. The 0.25Gy dose, which was able to induce an increment of clonal efficiency, did not induce cell transformation. The gene expression profile, which was obtained by comparing cells treated with the highest tested dose of 3Gy with the cells exposed to the lowest, not transforming, dose of 0.25Gy, identified several genes related to mitotic cell cycle and cholesterol biosynthesis. Conclusion: Our study showed that the up-regulation of genes belonging to the Spindle Assembly Checkpoint and mitosis progression could support the transforming ability of the 3Gy BALB/c3T3 exposed cells, probably through the involvement of genomic instability. Gene transcripts involved into cholesterol biosynthesis appear to be critical, as well. All these transcripts may be regarded as potential biomarkers of IR effects.","PeriodicalId":247564,"journal":{"name":"International Journal on Oncology and Radiotherapy","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115399156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-14DOI: 10.20944/preprints202012.0347.v1
Anoshia Afzal, M. Quinton, U. Farooque, S. Asadbeigi, B. Khan, S. Khan
Ovarian lymphoma is an infrequent disease, accounting for less than 1% of all non-Hodgkin lymphoma diagnosis. Symptoms include abnormal vaginal bleeding or discharge, abdominal pain, and urinary obstruction due to the large mass. In our case, a 60-year-old woman, underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy, as she presented with low-grade follicular lymphoma (FL) in both the ovaries, and the left ovary was observed to be enlarged. The tumor is categorized as lymphoma based upon immunohistochemical markers. Computed tomography (CT) scan of the chest, abdomen, and pelvis and bone marrow biopsy are important for the staging of primary lymphoma of the ovary. The first-line chemotherapy regimen includes rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (R-CHOP) for rapidly proliferative non-Hodgkin lymphoma (NHL). Lymphomas with slower growth patterns can be treated with Bendamustine-Rituximab and don’t need aggressive R-CHOP treatment.
{"title":"Follicular Lymphoma Involving Bilateral Ovaries Following Routine Hysterectomy and Bilateral Salpingo-Oophorectomy: An Incidental Finding","authors":"Anoshia Afzal, M. Quinton, U. Farooque, S. Asadbeigi, B. Khan, S. Khan","doi":"10.20944/preprints202012.0347.v1","DOIUrl":"https://doi.org/10.20944/preprints202012.0347.v1","url":null,"abstract":"Ovarian lymphoma is an infrequent disease, accounting for less than 1% of all non-Hodgkin lymphoma diagnosis. Symptoms include abnormal vaginal bleeding or discharge, abdominal pain, and urinary obstruction due to the large mass. In our case, a 60-year-old woman, underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy, as she presented with low-grade follicular lymphoma (FL) in both the ovaries, and the left ovary was observed to be enlarged. The tumor is categorized as lymphoma based upon immunohistochemical markers. Computed tomography (CT) scan of the chest, abdomen, and pelvis and bone marrow biopsy are important for the staging of primary lymphoma of the ovary. The first-line chemotherapy regimen includes rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone (R-CHOP) for rapidly proliferative non-Hodgkin lymphoma (NHL). Lymphomas with slower growth patterns can be treated with Bendamustine-Rituximab and don’t need aggressive R-CHOP treatment.","PeriodicalId":247564,"journal":{"name":"International Journal on Oncology and Radiotherapy","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123547950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-12DOI: 10.51626/ijor.2020.01.00001
Purpose: Glioblastoma is the most common primary brain tumor with a poor prognosis. Although the standard of initial treatment is well defined, no recommendation exists in the relapse setting. This work focuses on the optimal strategy for recurrent glioblastoma. Methods: We performed a retrospective monocentric analysis of all recurrent glioblastoma adult patients treated since 2000 in one neuro-oncology center by re-irradiation, alone or combined with chemotherapy and/or surgery at first or second relapse. Results: Overall, 61 patients underwent a re-irradiation for glioblastoma relapse. Patient median age at diagnosis was 55 (27 to 76), 44% were women. At diagnosis, 77% underwent surgical resection and 23% were biopsied. Most of them (95%) received a Stuppregimen. After a median follow-up of 31.1 months, 44 patients (72%) had died and the median overall survival (mOS) was 39.8 months. Regardless of the time of treatment (first or second relapse), patients treated with radiation therapy concomitant to bevacizumab (RTbev, n=36) showed superior survival data compared to patients treated with radiation therapy alone (RTalone, n=17). At first relapse, median progression free survival (mPFS) of RTbev (n=19) was 9.9 versus 3.6 months for RTalone (n=6) (OR=3.98 (3.14-61.81); p=0.001). At second relapse, mPFS of RTbev (n=17) was 9.2 versus 5.4 months for RTalone (n=11) (OR=2.31 (1.18-7.75); p =0.03), and mOS of RTbev was 15.2 versus 9.1 months for RTalone (OR=3.60 (2.17-18.13); p=0.001). Conclusion: This retrospective monocentric analysis reports a favorable impact of bevacizumab adjunction to re-irradiation. The high mOS may be due to patient selection, but emphasis the relevance of a multidisciplinary approach.
{"title":"Glioblastoma Re-Irradiation: Impact of Concomitant Bevacizumab - Retrospective Series of 61 Cases","authors":"","doi":"10.51626/ijor.2020.01.00001","DOIUrl":"https://doi.org/10.51626/ijor.2020.01.00001","url":null,"abstract":"Purpose: Glioblastoma is the most common primary brain tumor with a poor prognosis. Although the standard of initial treatment is well defined, no recommendation exists in the relapse setting. This work focuses on the optimal strategy for recurrent glioblastoma.\u0000Methods: We performed a retrospective monocentric analysis of all recurrent glioblastoma adult patients treated since 2000 in one neuro-oncology center by re-irradiation, alone or combined with chemotherapy and/or surgery at first or second relapse.\u0000Results: Overall, 61 patients underwent a re-irradiation for glioblastoma relapse. Patient median age at diagnosis was 55 (27 to 76), 44% were women. At diagnosis, 77% underwent surgical resection and 23% were biopsied. Most of them (95%) received a Stuppregimen. After a median follow-up of 31.1 months, 44 patients (72%) had died and the median overall survival (mOS) was 39.8 months. Regardless of the time of treatment (first or second relapse), patients treated with radiation therapy concomitant to bevacizumab (RTbev, n=36) showed superior survival data compared to patients treated with radiation therapy alone (RTalone, n=17). At first relapse, median progression free survival (mPFS) of RTbev (n=19) was 9.9 versus 3.6 months for RTalone (n=6) (OR=3.98 (3.14-61.81); p=0.001). At second relapse, mPFS of RTbev (n=17) was 9.2 versus 5.4 months for RTalone (n=11) (OR=2.31 (1.18-7.75); p =0.03), and mOS of RTbev was 15.2 versus 9.1 months for RTalone (OR=3.60 (2.17-18.13); p=0.001).\u0000Conclusion: This retrospective monocentric analysis reports a favorable impact of bevacizumab adjunction to re-irradiation. The high mOS may be due to patient selection, but emphasis the relevance of a multidisciplinary approach.","PeriodicalId":247564,"journal":{"name":"International Journal on Oncology and Radiotherapy","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123509147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：